OR WAIT null SECS
July 24, 2024
Under the expanded agreement, Univercells and University of Pennsylvania will evaluate certain bioreactors for scalable gene therapy production.
July 19, 2024
Pluri’s newly launched CDMO business will manufacture two novel cell therapy product candidates for Kadimastem.
July 18, 2024
The acquisition adds a Phase III therapeutic peptide candidate to AstraZeneca’s late-stage pipeline for rare diseases.
July 17, 2024
The acquisition of EyeBio adds a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration to Merck’s pipeline.
July 16, 2024
The acquisition adds NM26, a Phase II-ready bispecific antibody for treating atopic dermatitis, to Johnson & Johnson’s immune-mediated and inflammatory disease portfolio.
July 12, 2024
With the acquisition, Olink will join Thermo Fisher’s Life Sciences Solutions business.
July 11, 2024
Through a multi-year collaboration, Pfizer and Evotec aim to conduct early discovery research for therapeutics against metabolic and infectious diseases.
July 04, 2024
The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
July 03, 2024
A strategic partnership between LenioBio and Labscoop is aimed at making scalable cell-free protein synthesis technology more accessible across North America.
This collaboration aims to support and accelerate clinical development of advanced and novel technologies.